- Home
- RYOJ vs TPST Comparison
RYOJ vs TPST Comparison
Compare RYOJ & TPST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RYOJ | TPST |
|---|---|---|
| Founded | 2015 | 2011 |
| Country | Japan | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 26.8M | 26.2M |
| IPO Year | N/A | 2012 |
Fundamental Metrics
Financial Performance| Metric | RYOJ | TPST |
|---|---|---|
| Price | $2.48 | $1.26 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $11.00 |
| AVG Volume (30 Days) | ★ 304.9K | 86.2K |
| Earning Date | 12-15-2025 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $295,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $19.04 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.56 | $1.22 |
| 52 Week High | $11.43 | $12.22 |
Technical Indicators
Market Signals| Indicator | RYOJ | TPST |
|---|---|---|
| Relative Strength Index (RSI) | 44.89 | 32.38 |
| Support Level | $1.85 | $1.23 |
| Resistance Level | $2.53 | $2.48 |
| Average True Range (ATR) | 0.40 | 0.06 |
| MACD | -0.11 | 0.01 |
| Stochastic Oscillator | 7.44 | 36.36 |
Price Performance
Historical ComparisonAbout RYOJ rYojbaba Co. Ltd.
rYojbaba Co Ltd is engaged in improving and restoring physical and mental health diminished by work-related stress through consulting and health services. The company provides consulting services to labor unions and companies wishing to build constructive relationships with labor unions and health services to osteopathic clinics and osteopathic beauty salons to alleviate physical ailments created by work-related stress.
About TPST Tempest Therapeutics Inc.
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets. Company's small-molecule product candidate, amezalpat (previously known as TPST-1120), has completed a Phase 2 study in first-line hepatocellular carcinoma and the second small-molecule product candidate is TPST-1495, plans to initiate a Phase 2 study for in familial adenomatous polyposis.